T Cell Metabolism in Cancer Immunotherapy
- PMID: 32642279
- PMCID: PMC7341973
- DOI: 10.20900/immunometab20200020
T Cell Metabolism in Cancer Immunotherapy
Abstract
Immune checkpoint therapies aiming to enhance T cell responses have revolutionized cancer immunotherapy. However, although a small fraction of patients develops durable anti-tumor responses, the majority of patients display only transient responses, underlying the need for finding auxiliary approaches. Tumor microenvironment poses a major metabolic barrier to efficient anti-tumor T cell activity. As it is now well accepted that metabolism regulates T cell fate and function, harnessing metabolism may be a new strategy to potentiate T cell-based immunotherapies.
Keywords: ROS; T cell differentiation; T cell memory; adoptive cell therapy; cancer immunotherapy; glycolysis; immunometabolism; mitochondria.
Conflict of interest statement
CONFLICTS OF INTEREST VAB has patents on the PD-1 pathway licensed by Bristol-Myers Squibb, Merck, EMD-Serono, Boehringer Ingelheim, AstraZeneca, Novartis and Dako. The authors declare no other competing interests.
Figures



References
-
- Warburg O On the origin of cancer cells. Science. 1956;123:309–14. - PubMed
-
- Finkel T Oxygen radicals and signaling. Curr Opin Cell Biol. 1998;10:248–53. - PubMed
-
- Meng TC, Fukada T, Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell. 2002;9:387–99. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials